Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 636847, 11 pages
http://dx.doi.org/10.1155/2013/636847
Research Article

CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN- Responses

1Pfizer Vaccine Research, Ottawa Laboratories, 340 Terry Fox Drive, Suite 200, Ottawa, ON, Canada K2K 3A2
2CSL Limited, 45 Poplar Road, Parkville, VIC 3052, Australia

Received 10 December 2012; Accepted 13 February 2013

Academic Editor: Anshu Agrawal

Copyright © 2013 Michael J. McCluskie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. McCluskie and A. M. Krieg, “Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA,” Current Topics in Microbiology and Immunology, vol. 311, pp. 155–178, 2006. View at Google Scholar · View at Scopus
  2. O. S. Segaard, N. Lohse, Z. B. Harboe et al., “Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial,” Clinical Infectious Diseases, vol. 51, no. 1, pp. 42–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Sagara, R. D. Ellis, A. Dicko et al., “A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults,” Vaccine, vol. 27, no. 52, pp. 7292–7298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Rynkiewicz, M. Rathkopf, I. Sim et al., “Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers,” Vaccine, vol. 29, no. 37, pp. 6313–6320, 2011. View at Google Scholar
  5. G. E. D. Mullen, R. D. Ellis, K. Miura et al., “Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria,” PLoS ONE, vol. 3, no. 8, article e2940, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Halperin, G. van Nest, B. Smith, S. Abtahi, H. Whiley, and J. J. Eiden, “A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant,” Vaccine, vol. 21, no. 19-20, pp. 2461–2467, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. R. D. Ellis, G. E. D. Mullen, M. Pierce et al., “A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals,” Vaccine, vol. 27, no. 31, pp. 4104–4109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. L. Cooper, H. L. Davis, M. L. Morris et al., “CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study,” Journal of Clinical Immunology, vol. 24, no. 6, pp. 693–701, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. C. L. Cooper, H. L. Davis, M. L. Morris et al., “Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine,” Vaccine, vol. 22, no. 23-24, pp. 3136–3143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Cooper, H. L. Davis, J. B. Angel et al., “CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults,” AIDS, vol. 19, no. 14, pp. 1473–1479, 2005. View at Google Scholar · View at Scopus
  11. C. L. Cooper, J. B. Angel, I. Seguin, H. L. Davis, and D. W. Cameron, “CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years,” Clinical Infectious Diseases, vol. 46, no. 8, pp. 1310–1314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. D. Weeratna, M. J. McCluskie, Y. Xu, and H. L. Davis, “CpG DNA induces stronger immune responses with less toxicity than other adjuvants,” Vaccine, vol. 18, no. 17, pp. 1755–1762, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. S. K. Kim, G. Ragupathi, S. Cappello, E. Kagan, and P. O. Livingston, “Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates,” Vaccine, vol. 19, no. 4-5, pp. 530–537, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. D. T. O'Hagan, M. Singh, J. Kazzaz et al., “Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen,” Vaccine, vol. 20, no. 27-28, pp. 3389–3398, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. W. M. Li, W. H. Dragowska, M. B. Bally, and M. P. Schutze-Redelmeier, “Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes,” Vaccine, vol. 21, no. 23, pp. 3319–3329, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Maraskovsky, M. Schnurr, N. S. Wilson, N. C. Robson, J. Boyle, and D. Drane, “Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant,” Immunology and Cell Biology, vol. 87, no. 5, pp. 371–376, 2009. View at Publisher · View at Google Scholar
  17. I. D. Davis, W. Chen, H. Jackson et al., “Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10697–10702, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Nicholaou, L. M. Ebert, I. D. Davis et al., “Regulatory T-Cell-mediated attenuation of T-Cell responses to the NY-ESO-1ISCOMATRIX vaccine in patients with advanced malignant melanoma,” Clinical Cancer Research, vol. 15, no. 6, pp. 2166–2173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. I. H. Frazer, M. Quinn, J. L. Nicklin et al., “Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia,” Vaccine, vol. 23, no. 2, pp. 172–181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Drane, E. Maraskovsky, R. Gibson et al., “Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers,” Human Vaccines, vol. 5, no. 3, pp. 151–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Duewell, U. Kisser, K. Heckelsmiller et al., “ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells,” Journal of Immunology, vol. 187, no. 1, pp. 55–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. N. S. Wilson, B. Yang, A. B. Morelli et al., “ISCOMATRIX vaccines mediate CD8(+) T-cell cross-priming by a MyD88-dependent signaling pathway,” Immunology and Cell Biology, vol. 90, no. 5, pp. 540–552, 2012. View at Publisher · View at Google Scholar
  23. H. L. Davis, R. Weeranta, T. J. Waldschmidt, L. Tygrett, J. Schorr, and A. M. Krieg, “CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen,” Journal of Immunology, vol. 160, no. 2, pp. 870–876, 1998. View at Google Scholar · View at Scopus
  24. R. D. Weeratna, S. R. Makinen, M. J. McCluskie, and H. L. Davis, “TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848),” Vaccine, vol. 23, no. 45, pp. 5263–5270, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Bode, G. Zhao, F. Steinhagen, T. Kinjo, and D. M. Klinman, “CpG DNA as a vaccine adjuvant,” Expert Review of Vaccines, vol. 10, no. 4, pp. 499–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. E. Eyles, M. G. Hartley, T. R. Laws, P. C. F. Oyston, K. F. Griffin, and R. W. Titball, “Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS),” Microbial Pathogenesis, vol. 44, no. 2, pp. 164–168, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. E. Eyles, B. Unal, M. G. Hartley et al., “Immunodominant Francisella tularensis antigens identified using proteome microarray,” Proteomics, vol. 7, no. 13, pp. 2172–2183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Dasari, C. Smith, J. Zhong, G. Scott, W. Rawlinson, and R. Khanna, “Recombinant glycoprotein B vaccine formulation with toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus,” Journal of General Virology, vol. 92, no. 5, pp. 1021–1031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Jacobs, P. Duewell, K. Heckelsmiller et al., “An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma,” International Journal of Cancer, vol. 128, no. 4, pp. 897–907, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Schnurr, M. Orban, N. C. Robson et al., “ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II,” Journal of Immunology, vol. 182, no. 3, pp. 1253–1259, 2009. View at Google Scholar · View at Scopus
  31. P. Ahmad-Nejad, H. Hacker, M. Rutz, S. Bauer, R. M. Vabulas, and H. Wagner, “Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments,” European Journal of Immunology, vol. 32, no. 7, pp. 1958–1968, 2002. View at Publisher · View at Google Scholar
  32. T. Maurer, A. Heit, H. Hochrein et al., “CpG-DNA aided cross-presentation of soluble antigens by dendritic cells,” European Journal of Immunology, vol. 32, no. 8, pp. 2356–2364, 2002. View at Publisher · View at Google Scholar